Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments

Amneal Pharmaceuticals (AMRX) said Monday that it has expanded its biosimilar portfolio to eight by adding ADL018, a proposed biosimilar of Novartis' (NVS) Xolair, or omalizumab, to its pipeline. The

MT NewswiresJul 1 21:49

Goldman Sachs Sticks to Their Buy Rating for Novartis AG (NOVN)

TipRanksJul 1 17:25

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

Yahoo FinanceJun 27 00:56

Exsilio Therapeutics Launches With $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases

Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, In

PR NewswireJun 25 17:00

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific

BusinesswireJun 25 04:05

Nestle Carefully Targets Weight-Loss Drug Users With New Food Line

Last month, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management. The Euro

BenzingaJun 21 18:18